This issue explores how patients have responded to the digital transformation and why 86% of tech professionals said the pharma digital moment has arrived.
In our July Patient Services Report, we provide an in-depth look at the recent rare disease market and evaluate the investment biopharma is making to enhance patient and HCP support in this space.
Certain pandemic driven trends will continue to persist, thus having lasting impacts on how we develop commercial strategies.
Patient barriers and HCP challenges result in 84% of patients making errors in self-injecting and 45% of patients skipping and avoiding their injections altogether.
In our April Patient Services Report, we explain how to measure patient support programs to assess their impact on patient adherence.
In the March Patient Services Report, we share insights on how clients are navigating this and recent technology and model innovations that have enabled success.
Patient adherence has become a competitive driver for the life sciences industry to realize the full clinical potential of their therapies and achieve even greater commercial success.
In our February Patient Services Report, VMS explores why patient adherence has become a competitive driver and is no longer optional for biopharma to invest in.
Here's what we believe are the most notable trends for 2021 and a few of our takeaways from the CEC and JP Morgan Healthcare conference this month
VMS Clinical Nurse Educators explain in this PM360 article how biopharma companies can support patient caregivers
VMS continually conducts primary and secondary research to identify the latest trends in the behavioral health space
Biopharma is addressing patient adherence during COVID-19, by leveraging predictive analytics and tech-enabled support models like OneVoiceTM
Read VMS CEO Andrea Heslin Smiley’s comments in this MM&M e-book
Industry also can play a role in supporting patient transitions to ensure the safe use of prescribed products and therapy management
Read VMS SVP Abigail Mallon’s comments in this PharmaVOICE article
Results of a healthcare professional survey we conducted on behalf of our biopharma clients
An interview with VMS CEO Andrea Heslin Smiley in the American Nurses Foundation newsletter
Read VMS SVP Abigail Mallon’s comments in this PharmaVOICE article
PharmaVOICE article illustrates why VMS clinical educators are driven to help patients on a 1:1 basis to manage chronic illnesses
Across our Biopharma programs, numerous patient and HCP insights demonstrate the large and growing impact CNEs are having
Read VMS SVP Abigail Mallon’s comments in PM360 magazine
PM360 magazine selected the VMS Insight Incubator™ as one of the most innovative services in the biopharma industry in 2019
The pandemic remains a highly prevalent factor requiring biopharma to deploy innovative HCP and patient engagement for the new normal
Biopharma R&D innovation and the role of Clinical Nurse Educators
Market forces and pandemic-related trends are increasing biopharma’s need to focus on areas where Clinical Nurse Educators can drive impact
Risk of patient non-adherence is at an all-time high
Patients receiving health coaching were almost 4X as likely to be adherent to medications
VMS shares recent insights from our Clinical Educators
Patient adherence is at the forefront of the conversation and is becoming a top business priority for Biopharma this year.